Chautauqua Capital Management, a division of Baird Asset Management, released its second quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. Global equity markets experienced a significant shift during the quarter, moving from notable losses to reaching new highs. Markets fell following the President’s announcement of unexpectedly severe tariffs, which raised recession fears. After a brief pause on tariffs, markets regained confidence, closing the quarter at or near all-time highs. The Baird Chautauqua International Growth Fund underperformed its benchmark during the quarter.

In the second-quarter 2025 investor letter, Baird Chautauqua International and Global Growth Fund highlighted Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The one-month return of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was -2.89%, and its shares lost 46.36% of their value over the last 52 weeks. On September 26, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock closed at $563.90 per share, with a market capitalization of $59.766 billion.

Baird Chautauqua International and Global Growth Fund stated in its second quarter 2025 investor letter that “Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported mixed top-line results from a pipeline drug, itepekimab, in Chronic Obstructive Pulmonary Disease (COPD), with one of the two trials meeting expectations. While itepekimab is not expected to be a core driver of Regeneron’s shares, other drug candidates in its pipeline continue to advance.”

According to data, 73 hedge fund portfolios held Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at the end of the second quarter, up from 66 in the previous quarter. In the second quarter of 2025, Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) total revenues reached $3.7 billion, representing a 4% growth compared to the previous year. While acknowledging the potential of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) as an investment, it is believed that certain AI stocks offer greater upside potential and carry less downside risk.

Read more at Yahoo Finance: Here’s Why Regeneron Pharmaceuticals (REGN) Fell in Q2